Novartis buoyed by trial success in early-stage breast cancer

The company's logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd WiegmannBreast cancer drug key to Swiss group's growth ambitionsKisqali breast cancer drug cut the risk of recurrence in women who were diagnosed at an early stage of the disease in a pivotal trial, providing a confidence boost for the drugmaker's growth prospects.

The late-stage trial of the drug in a type of cancer that grows in response to hormones showed that Kisqali significantly cut the risk of recurrence when used with standard endocrine therapy, rather than endocrine therapy alone, the firm added. He added that the trial update would be a boost to low market confidence in targets issued by Chief Executive Vas Narasimhan for annual sales growth of 4% through 2027 and a core operating income margin of 40% from 2027.

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Novartis gets positive result from breast-cancer drug trialThe Phase 3 trial, named Natalee, was stopped early as the primary endpoint has been met, Novartis said.
Source: MarketWatch - 🏆 3. / 97 Read more »